CN105560513A - 治疗面神经麻痹的中药组合物及其制备方法和应用 - Google Patents
治疗面神经麻痹的中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN105560513A CN105560513A CN201510996356.XA CN201510996356A CN105560513A CN 105560513 A CN105560513 A CN 105560513A CN 201510996356 A CN201510996356 A CN 201510996356A CN 105560513 A CN105560513 A CN 105560513A
- Authority
- CN
- China
- Prior art keywords
- herba
- chinese medicine
- medicine composition
- parts
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 208000006373 Bell palsy Diseases 0.000 title abstract 5
- 229940079593 drug Drugs 0.000 claims abstract description 42
- 241001116755 Selliguea Species 0.000 claims abstract description 30
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000006187 pill Substances 0.000 claims description 20
- 241000505911 Tadehagi Species 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 238000007493 shaping process Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 238000010792 warming Methods 0.000 abstract description 5
- 206010010904 Convulsion Diseases 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 4
- 230000036461 convulsion Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000722953 Akebia Species 0.000 abstract 1
- 241000717679 Mosla Species 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 208000004929 Facial Paralysis Diseases 0.000 description 15
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 15
- 239000000796 flavoring agent Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 235000012907 honey Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 241000255791 Bombyx Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000903946 Clematidis Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 241000131808 Scolopendra Species 0.000 description 2
- 241000522620 Scorpio Species 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 210000000256 facial nerve Anatomy 0.000 description 2
- -1 fluidizer Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000009490 scorpio Substances 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000036770 Akebia trifoliata Species 0.000 description 1
- 235000012980 Akebia trifoliata Nutrition 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000143476 Bidens Species 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001549572 Elsholtzia splendens Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 244000119461 Garcinia xanthochymus Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 241001506304 Kadsura japonica Species 0.000 description 1
- 241001083838 Lardizabalaceae Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000196124 Polypodiaceae Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 241001077909 Sigesbeckia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000001547 Tadehagi triquetrum Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241001125929 Trisopterus luscus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000031748 disorder of facial skeleton Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 201000003079 ectropion Diseases 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗面神经麻痹的中药组合物,属于面神经麻痹的中药治疗领域。本发明首先公开了一种治疗面神经麻痹的中药组合物,包括以下各原料药:香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红。本发明中药组合物按照中药常规制剂方法将其制备成适宜的临床制剂。本发明中药组合物具有温中理气、温经通脉、祛风定惊、通络止痛之功效,临床疗效表明本发明中药组合物对于面神经麻痹疗效确切可靠,标本兼治,临床应用安全,无任何毒副作用。
Description
技术领域
本发明涉及一种中药组合物,尤其涉及一种治疗面神经麻痹的中药组合物及其制备方法和用途,属于面神经麻痹的中药治疗领域。
背景技术
面神经麻痹,是一种比较复杂的面部疾病,它是一种常见病、多发病,不受年龄限制。临床表现为病灶侧面部表情肌瘫痪、前额皱纹消失、眼裂扩大。面神经麻痹分为周围性和中枢性两种。周围性面神经麻痹是指面神经运动纤维发生病变所引起的面瘫。中枢性面神经麻痹是指病损位于面神经核以上至大脑皮层中枢之间,即当一侧皮质脑干束受损时引起的面瘫。
目前治疗面神经麻痹的药物有很多,包括针灸、口服及注射西药等。但是针灸效果慢,需要长时间治疗,西药大多有副作用。而中药学作为我国的传统医学,具有标本兼治、作用强、见效快、药效持久的优点,且没有依赖性、耐药性以及毒副作用,因此,开发一种对面神经麻痹具有确切治疗效果的中药组合物,将具有十分重要的临床意义。
发明内容
本发明所要解决的技术问题是提供一种治疗面神经麻痹的中药组合物,该中药组合物对面神经麻痹的治疗见效快、疗效确切、无毒副作用。
本发明所要解决的另一个技术问题是提供一种所述中药组合物的制备方法。
为解决上述技术问题,本发明所采取的技术方案是:
本发明首先公开了一种治疗面神经麻痹的中药组合物,包括以下各原料药:香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红。
各原料药的重量份为:香薷42-48份、木通42-48份、海风藤35-40份、地耳草35-40份、桑枝15-25份、鹅掌金星草5-10份、橘红5-10份;优选的,各原料药的重量份为:香薷45份、木通45份、海风藤37份、地耳草37份、桑枝20份、鹅掌金星草7份、橘红7份。
香薷为唇形科植物海州香薷的带花全草。性味:辛,微温。入肺、胃经。功能主治:发汗解暑,行水散湿,温胃调中。治夏月感寒饮冷,头痛发热,恶寒无汗,胸痞腹痛,呕吐腹泻,水肿,脚气。
木通为木通科植物白木通或三叶木通、木通的木质茎。性味:苦,凉。入心、小肠、膀胱经。功能主治:泻火行水,通利血脉。治小便赤涩,淋浊,水肿,胸中烦热,喉痹咽痛,遍身拘痛,妇女经闭,乳汁不通。
海风藤为胡椒科植物细叶青蒌藤的藤茎。性味:辛苦,微温。入心、肾二经。功能主治:祛风湿,通经络,理气。治风寒湿痹,关节疼痛,筋脉拘挛,跌打损伤,哮喘,久咳。
地耳草为藤黄科植物地耳草的全草。性味:苦甘,凉。功能主治:清热利湿,消肿解毒。治传染性肝炎,泻痢,小儿惊风,疳积,喉蛾,肠痈,疖肿,蛇咬伤。
桑枝为桑科植物桑的嫩枝。性味:苦,平。入肝经。功能主治:祛风湿,利关节,行水气。治风寒湿痹,四肢拘挛,脚气浮肿,肌体风痒。
鹅掌金星草为水龙骨科植物金鸡脚的全草或带根全草。性味:苦,凉。功能主治:清热。凉血,利尿,解毒。治伤寒热病,烦渴,惊风,扁桃体炎,细菌性痢疾,慢性肝炎,血淋,便血,痈肿疔疮。
橘红为芸香科植物福橘或朱橘等多种橘类的果皮的外层红色部分。性味:辛苦,温。功能主治:消痰,利气,宽中,散结。治风寒痰嗽,恶心,吐水,胸痛胀闷。
本发明中药组合物是基于发明人对面神经麻痹的深层发病机理的研究及其治疗原则,同时依据发明人多年临床经验和药理学研究成果,筛选出活血通络,祛风解毒,散寒解表的的原料药,按照一定的重量配比组方而成。
本发明进一步公开了一种治疗面神经麻痹的中药组合物,包括以下各原料药:香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草、橘红、豨莶草、山藿香和葫芦茶。
优选的,各原料药的重量份是:香薷42-48份、木通42-48份、海风藤35-40份、地耳草35-40份、豨莶草25-35份、桑枝15-25份、山藿香15-25份、葫芦茶5-10份、鹅掌金星草5-10份、橘红5-10份;
最优选的,各原料药的重量份为:香薷45份、木通45份、海风藤37份、地耳草37份、豨莶草30份、桑枝20份、山藿香20份、葫芦茶7份、鹅掌金星草7份、橘红7份。
豨莶草为菊科植物腺梗豨莶SiegesbeckiapubescensMakino的地上部分。性味:性寒,味辛、苦。功能主治:祛风湿,利关节,解毒。用于风湿痹痛、筋骨无力、腰膝酸软、四肢麻痹、半身不遂、风疹湿疮。
山藿香为唇形科植物山藿香的全草。性味:辛,凉。入肺;大肠经。功能主治:凉血散瘀,消肿解毒。治吐血,肠风下血,跌打损伤,痈肿,痔疮,流火。
葫芦茶为豆科山蚂蝗属植物葫芦茶Desmodiumtriquetrum(L.)DC.,以全株入药。性味:微苦、涩,凉。功能主治:清热解毒,消积利湿,杀虫防腐。用于预防中暑,感冒发热,咽喉肿痛,肾炎,黄疸型肝炎,肠炎,细菌性痢疾,小儿疳积,妊娠呕吐,菠萝中毒,小儿硬皮病。
本发明由香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红制备的中药组合物对面神经麻痹具有一定的治疗效果,有效率达71.0%。在香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红的基础上分别添加了以下6组药物:(1)防风、威灵仙、白芷;(2)白僵蚕、羌活、荆芥;(3)蜈蚣、茯苓、钩藤;(4)甘草、升麻、白附子;(5)川芎、全蝎、细辛;(6)豨莶草、山藿香、葫芦茶;将上述6组药物组合物分别制备中药组合物,考察其对面神经麻痹的治疗效果。实验结果表明,在香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红基础上添加豨莶草、山藿香、葫芦茶对病人的有效率高达99.0%,显著高于其它组合。说明香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红与豨莶草、山藿香、葫芦茶配伍在一起具有确切的协同增效功效,有效提高了治疗面神经麻痹的有效率。相比之下,将香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红与其它几种药物配伍在一起后,对于提高面神经麻痹治疗效果的作用不明显。
本发明各药配伍在一起起到温中理气、温经通脉、祛风定惊、通络止痛之功效。本发明中药组合物对于面神经麻痹标本兼治,临床疗效观察证实,本发明中药组合物对于面神经麻痹疗效确切可靠、真实。本发明中药组合物无毒无害,安全可靠,服用后无不良反应,临床使用安全。
本发明所用的各味原料药都可以在医药商店购买得到。
在本发明中药组合物基础上,添加适宜的辅料或载体按照中药常规制剂方法将其制备成治疗复发性口疮的适宜的临床制剂;优选为口服制剂。
所述的口服制剂包括丸剂、散剂、颗粒剂、胶囊剂、片剂、口服液或滴丸剂。
所述的载体或辅料是指药学领域常规的载体或辅料,例如:稀释剂、崩裂剂、润滑剂、赋形剂、粘合剂、助流剂、填充剂、表面活性剂等;另外,还可以在组合物中加入其它辅助剂,如香味剂和甜味剂。所述稀释剂可以是一种或几种增加片剂重量和体积的成分,常用的稀释剂包括乳糖、淀粉、预胶化淀粉、微晶纤维素、山梨醇、甘露醇以及无机钙盐等;其中最常用为乳糖、淀粉、微晶纤维素。所述崩解剂可以为交联聚乙烯吡咯烷酮,交联羧甲基纤维素钠、海藻酸、微晶纤维素中之一种或几种混合物;其中以交联聚乙烯吡咯烷酮,交联羧甲基纤维素钠为佳。所述的润滑剂包括硬脂酸,硬脂酸钠,硬脂酸镁,硬脂酸钙,聚乙二醇,滑石粉,氢化植物油中之一种或几种混合物;其中以硬脂酸镁最为适宜。所述的粘合剂可以是一种或几种有利于制粒的成分;可以是淀粉浆,羟丙基甲基纤维素,聚乙烯吡咯烷酮,以聚乙烯吡咯烷酮的乙醇水溶液为佳。所述助流剂可以为微粉硅胶、滑石粉、三硅酸镁中之一种或几种混合物。所述表面活性剂可以为一种或几种能够提高润湿性和增加药物溶出的成分,常用为十二烷基硫酸钠。
本发明中药组合物的一种制备方法,包括以下步骤:将本发明的各原料药按所述重量份配比称取后,粉碎,过筛(例如可以是100-300目筛),即得。当然,也可以将各原料药粉碎后,加入制剂成型所需的辅料或赋型剂,按照常规方法制备成所需剂型。
本发明中药组合物的另一种制备方法:按所述重量份称取各原料药;将各原料药用水煎煮,合并煎煮液,过滤,滤液浓缩成清膏,加入制剂成型的辅料或赋型剂,制剂成型,即得。
本发明中药组合物的用法与用量:本发明的用药量取决于具体剂型、病人的年龄、健康状况等因素。作为指导:用法用量:丸剂,每丸丸剂含0.4克生药,每次口服1至2丸,一日2次,10天为一个疗程,一般需要治疗2-3个疗程。
本发明技术方案与现有技术相比,具有以下有益效果:
本发明中药组合物的配伍合理,能够明显提高治疗面神经麻痹的有效率,疗效确切。本发明中药组合物为纯中药制剂,标本兼治,无副作用,且制备工艺简单,具有良好的应用前景。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但是应理解所述实施例仅是范例性的,不对本发明的范围构成任何限制。本领域技术人员应该理解的是,在不偏离本发明的精神和范围下可以对本发明技术方案的细节和形式进行修改或替换,但这些修改或替换均落入本发明的保护范围。
实施例1丸剂的制备
按以下重量称取各原料药:香薷42g、木通42g、海风藤35g、地耳草35g、桑枝15g、鹅掌金星草5g、橘红5g;将上述各原料药加水煎煮二次,第一次加4倍重量的水,煎煮2小时,第二次加3倍重量的水,煎煮1.5小时;将煎煮液合并,滤过,滤液浓缩至相对密度为1.17-1.19(60℃)的清膏;加适量炼蜜,混匀,制备成每丸4g的药丸。
实施例2丸剂的制备
按以下重量称取各原料药:香薷48g、木通48g、海风藤40g、地耳草40g、桑枝25g、鹅掌金星草10g、橘红10g;将上述各原料药加水煎煮二次,第一次加4倍重量的水,煎煮2小时,第二次加3倍重量的水,煎煮1.5小时;将煎煮液合并,滤过,滤液浓缩至相对密度为1.17-1.19(60℃)的清膏;加适量炼蜜,混匀,制备成每丸4g的药丸。
实施例3丸剂的制备
按以下重量称取各原料药:香薷45g、木通45g、海风藤37g、地耳草37g、桑枝20g、鹅掌金星草7g、橘红7g;将上述各原料药加水煎煮二次,第一次加4倍重量的水,煎煮2小时,第二次加3倍重量的水,煎煮1.5小时;将煎煮液合并,滤过,滤液浓缩至相对密度为1.17-1.19(60℃)的清膏;加适量炼蜜,混匀,制备成每丸4g的药丸。
实施例4丸剂的制备
按以下重量称取各原料药:香薷42g、木通42g、海风藤35g、地耳草35g、豨莶草25g、桑枝15g、山藿香15g、葫芦茶5g、鹅掌金星草5g、橘红5g;将上述各原料药加水煎煮二次,第一次加4倍重量的水,煎煮2小时,第二次加3倍重量的水,煎煮1.5小时;将煎煮液合并,滤过,滤液浓缩至相对密度为1.17-1.19(60℃)的清膏;加适量炼蜜,混匀,制备成每丸4g的药丸。
实施例5丸剂的制备
按以下重量称取各原料药;香薷48g、木通48g、海风藤40g、地耳草40g、豨莶草35g、桑枝25g、山藿香25g、葫芦茶10g、鹅掌金星草10g、橘红10g;将上述各原料药加水煎煮二次,第一次加4倍重量的水,煎煮2小时,第二次加3倍重量的水,煎煮1.5小时;将煎煮液合并,滤过,滤液浓缩至相对密度为1.17-1.19(60℃)的清膏;加适量炼蜜,混匀,制备成每丸4g的药丸。
实施例6丸剂的制备
按以下重量称取各原料药:香薷45g、木通45g、海风藤37g、地耳草37g、豨莶草30g、桑枝20g、山藿香20g、葫芦茶7g、鹅掌金星草7g、橘红7g;将上述各原料药加水煎煮二次,第一次加4倍重量的水,煎煮2小时,第二次加3倍重量的水,煎煮1.5小时;将煎煮液合并,滤过,滤液浓缩至相对密度为1.17-1.19(60℃)的清膏;加适量炼蜜,混匀,制备成每丸4g的药丸。
实验例1应用本发明中药组合物治疗面神经麻痹的临床疗效观察试验
一、一般资料:
700例患者均符合面神经麻痹的诊断标准,将患者随机分成7组,每组100例;7组在性别、年龄、病程及病情严重程度上差异无显著性。诊断标准:面部前额皱纹消失、眼裂扩大、鼻唇沟平坦、口角下垂,露齿时口角向健侧偏歪。病侧不能作皱额、蹙眉、闭目、鼓气和噘嘴等动作。鼓腮和吹口哨时,因患侧口唇不能闭合而漏气。进食时,食物残渣常滞留于病侧的齿颊间隙内,并常有口水自该侧淌下。由于泪点随下睑外翻,使泪液不能按正常引流而外溢。
二、药物制备
中药组合物1:按照以下重量称取各原料药:香薷45g、木通45g、海风藤37g、地耳草37g、桑枝20g、鹅掌金星草7g、橘红7g;
将上述各原料药加水煎煮二次,第一次加4倍重量的水,煎煮2小时,第二次加3倍重量的水,煎煮1.5小时;将煎煮液合并,滤过,滤液浓缩至相对密度为1.17-1.19(60℃)的清膏;加适量炼蜜,混匀,制备成每丸4g的药丸。
中药组合物2:在中药组合物1基础上添加防风30g、威灵仙20g、白芷7g;
中药组合物3:在中药组合物1基础上添加白僵蚕30g、羌活20g、荆芥7g;
中药组合物4:在中药组合物1基础上添加蜈蚣30g、茯苓20g、钩藤7g;
中药组合物5:在中药组合物1基础上添加甘草30g、升麻20g、白附子7g;
中药组合物6:在中药组合物1基础上添加川芎30g、全蝎20g、细辛7g;
中药组合物7:在中药组合物1基础上添加豨莶草30g、山藿香20g、葫芦茶7g;
中药组合物2-7的制备方法同中药组合物1。
三、治疗方法
分别用上述中药组合物1-7的丸剂对上述7组面神经麻痹患者进行治疗,各患者均随访1年;口服,一次2丸(0.4g生药/丸),一日2次,早晚各一次,治疗10天;服药期间停服其它相关药物及其它治疗。
四、疗效评定标准
治愈:上述症状全部消失,面部恢复正常。
显效:上述症状明显减轻,面部有所好转。
无效:通过治疗后上述症状无减轻或加重。
有效率:[(治愈例数+有效例数)/总病例数]×100%。
五、临床观察结果
临床观察结果见表1。
表1不同中药组合物治疗面神经麻痹的统计结果
结果表明,由香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红制备的中药组合物1对面神经麻痹具有一定的治疗效果,有效率达71.0%。在香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红基础上,添加豨莶草、山藿香、葫芦茶,对治疗面神经麻痹的有效率显著提高,达到99.0%。
以上结果说明,香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红与豨莶草、山藿香、葫芦茶之间具有显著的协同增效作用,将其配伍在一起能够显著提高治疗面神经麻痹的有效率。相比之下,将香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红与其它几种药物配伍在一起后,对于提高面神经麻痹治疗效果的作用不明显。安全性观察发现,没有观察到任何临床不良反应,表明本发明中药组合物临床应用安全、无毒副作用。
试验例2中药组合物治疗面神经麻痹的典型病例
病例1:赵某,男,53岁,患者右侧面肌、斜方肌无力,右侧额纹、鼻唇沟浅,右眼埋睫征消失,经诊断为面神经麻痹。服用本发明实施例6所制备的药物1个疗程后,症状有所减轻,服用2个疗程后,症状全部消失,痊愈,1年后随访未见复发。
病例2:吴某某,女,42岁,患者因受风寒出现口眼歪斜,不能鼓腮,喝水时口角漏水,眼裂增大,眼睑不能闭合。服用本发明实施例6所制备的药物3个疗程后,症状全部消失。
病例3:李某,女,36岁,起床后右侧耳根部突发疼痛,口角鼻向右歪斜。服用西药一个月后无效。然后服用本发明实施例6所制备的药物一个疗程后,开始好转,又服用一个疗程后,痊愈。半年后随访未见复发。
Claims (10)
1.一种治疗面神经麻痹的中药组合物,其特征在于,包括以下各原料药:香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草和橘红。
2.按照权利要求1所述的中药组合物,其特征在于,各原料药的重量份为:香薷42-48份、木通42-48份、海风藤35-40份、地耳草35-40份、桑枝15-25份、鹅掌金星草5-10份、橘红5-10份。
3.按照权利要求2所述的中药组合物,其特征在于,各原料药的重量份为:香薷45份、木通45份、海风藤37份、地耳草37份、桑枝20份、鹅掌金星草7份、橘红7份。
4.一种治疗面神经麻痹的中药组合物,其特征在于,包括以下各原料药:香薷、木通、海风藤、地耳草、桑枝、鹅掌金星草、橘红、豨莶草、山藿香和葫芦茶。
5.按照权利要求4所述的中药组合物,其特征在于,各原料药的重量份为:香薷42-48份、木通42-48份、海风藤35-40份、地耳草35-40份、豨莶草25-35份、桑枝15-25份、山藿香15-25份、葫芦茶5-10份、鹅掌金星草5-10份、橘红5-10份。
6.按照权利要求5所述的中药组合物,其特征在于,各原料药的重量份为:香薷45份、木通45份、海风藤37份、地耳草37份、豨莶草30份、桑枝20份、山藿香20份、葫芦茶7份、鹅掌金星草7份、橘红7份。
7.按照权利要求1至6任何一项所述的中药组合物,其特征在于,按照中药常规制剂方法将其制备成适宜的临床制剂,优选为口服制剂。
8.按照权利要求7所述的中药组合物,其特征在于,所述的口服制剂包括丸剂、散剂、颗粒剂、胶囊剂、片剂、口服液或滴丸剂。
9.一种制备权利要求1至6任何一项所述中药组合物的方法,其特征在于,包括以下步骤:称取各原料药;将各原料药用水煎煮,合并煎煮液,过滤,滤液浓缩成清膏,加入制剂成型的辅料或赋型剂,制剂成型,即得。
10.权利要求1至6任何一项所述的中药组合物在制备治疗面神经麻痹的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510996356.XA CN105560513A (zh) | 2015-12-26 | 2015-12-26 | 治疗面神经麻痹的中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510996356.XA CN105560513A (zh) | 2015-12-26 | 2015-12-26 | 治疗面神经麻痹的中药组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105560513A true CN105560513A (zh) | 2016-05-11 |
Family
ID=55871527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510996356.XA Pending CN105560513A (zh) | 2015-12-26 | 2015-12-26 | 治疗面神经麻痹的中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105560513A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103623268A (zh) * | 2013-12-04 | 2014-03-12 | 张国显 | 神经康复再造丸及其制备方法 |
-
2015
- 2015-12-26 CN CN201510996356.XA patent/CN105560513A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103623268A (zh) * | 2013-12-04 | 2014-03-12 | 张国显 | 神经康复再造丸及其制备方法 |
Non-Patent Citations (3)
Title |
---|
ZHENBO LI: "Facial Paralysis Treatment", 《THE JOURNAL OF CHINESE MEDICINE》 * |
万桂华: "豨莶草治疗面神经瘫痪", 《北京中医杂志》 * |
胡献国: "面瘫的药粥疗法", 《药膳食疗》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103735721B (zh) | 一种治疗急性传染性结膜炎的中药 | |
CN103432559B (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
CN103816454B (zh) | 一种治疗动脉硬化的纯中药胶囊 | |
CN102988701A (zh) | 一种用于治疗便秘的中药及其制备工艺 | |
CN105535371A (zh) | 一种治疗膝关节滑膜炎的中药 | |
CN103656572A (zh) | 一种中药组合物、中药合剂和膏药及其制备方法 | |
CN103638234B (zh) | 一种治疗耳鸣的中药组合物、制剂及其制备方法 | |
CN105521332A (zh) | 治疗肛裂的中药组合物及其制备方法和应用 | |
CN105688035A (zh) | 一种治疗心脑血管疾病的中药制剂 | |
CN104474308A (zh) | 一种治疗急性膀胱炎的中药组合物 | |
CN104606661A (zh) | 一种治疗剖宫产后缺乳的中药催乳剂及其制备方法 | |
CN104013836A (zh) | 一种治疗脑中风后遗症的中药组合物 | |
CN104173775A (zh) | 颈源性头痛中药组合物及制备方法 | |
CN103830486A (zh) | 一种治疗梅核气的中药 | |
CN103356797A (zh) | 一种治疗肾结石的中药组合物 | |
CN103990014A (zh) | 一种治疗湿热型痤疮的中药混合物 | |
CN105560513A (zh) | 治疗面神经麻痹的中药组合物及其制备方法和应用 | |
CN103893328A (zh) | 一种治疗乳腺增生的中药药丸 | |
CN102988883B (zh) | 一种治疗肝炎的药物及其制备方法 | |
CN102327423A (zh) | 能够有效治疗更年期综合征的中成药及中药汤剂 | |
CN105287798A (zh) | 降脂瘦身复原丸 | |
CN105343653A (zh) | 一种治疗噤口痢的中药制剂 | |
CN105560856A (zh) | 治疗周围神经炎的中药组合物及其制备方法和应用 | |
CN104398853A (zh) | 一种治疗耳鸣的中药配方及其制备方法 | |
CN103784851A (zh) | 一种治疗美尼尔氏综合症的中药制剂及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160511 |